secwatch.observer — SEC 8-K summary
======================================

Issuer:     GoodRx Holdings, Inc. (GDRX)
CIK:        0001809519
Form:       8-K
Filed at:   2023-08-09T23:59:59+00:00
Accession:  0001628280-23-028384
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

GoodRx Q2 revenue $189.7M beats guidance; Adj. EBITDA $53.5M
------------------------------------------------------------

- Total revenue $189.7M, exceeding previously announced guidance; net income $58.8M (includes $46.7M tax benefit).
- Adjusted EBITDA $53.5M (28.2% margin), also above guidance; adjusted net income $28.4M.
- Prescription transactions revenue and volume returned to year-over-year growth.
- Over 500,000 prescribers engaged via Provider Mode; over 7M consumers of prescription offerings.
- New program with CVS Caremark and expanded direct pharmacy contracts.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1809519/000162828023028384/0001628280-23-028384-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1809519/000162828023028384/gdrx-20230809.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-028384

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer